Research
The Lancet publishes comment on mitapivat in RISE UP trial
The excerpt identifies mitapivat as the subject of a comment on the RISE UP trial but gives no trial results.
The original reports on this story are listed below.
More top stories
Drugs and FDA
Moderna and Merck report vaccine cut melanoma recurrence or death risk by 42%
In a phase 3 trial, intismeran plus Keytruda reduced melanoma recurrence or death risk by 42% versus Keytruda alone.
Insurance
Employer health premiums rise 5%, while workers’ family contributions rise 9%
KFF found the average family premium reached $28,303 in 2026, while workers paid an average $7,471 toward it, up 9%.
Infectious disease
France reports first known human Shamonda virus infection
The patient was severely immunocompromised and died in early October. Investigations into the infection and its possible role in the death are ongoing.